XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection. (2022)

First Author: Gerber PP
Attributed to:  MRC Transition Support CSF Nicholas Matheson funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-34339-w

PubMed Identifier: 36385143

Publication URI: http://europepmc.org/abstract/MED/36385143

Type: Journal Article/Review

Volume: 13

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723